Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma

Autor: Daniele Generali, Navid Sobhani, Fabrizio Zanconati, Fabiola Giudici, Marco Confalonieri, Silvia Paola Corona, Deborah Bonazza, Giandomenico Roviello, M. Cortale, M. Milione, A. Guglielmi, Cristina Bottin, Anna Ianza, T. Pivetta, Clara Rizzardi
Přispěvatelé: Sobhani, N, Roviello, G, Pivetta, T, Ianza, A, Bonazza, D, Zanconati, F, Giudici, F, Bottin, C, Corona, Sp, Guglielmi, A, Rizzardi, C, Milione, M, Cortale, M, Confalonieri, M, Generali, D.
Rok vydání: 2018
Předmět:
0301 basic medicine
Oncology
Male
Mesothelioma
Immunotherapy
Malignant pleural mesothelioma
Programmed cell death-ligand 1
Tumour-infiltrating lymphocytes
Lung Neoplasms
Survival
medicine.medical_treatment
Kaplan-Meier Estimate
Clinical-Trial
B7-H1 Antigen
0302 clinical medicine
Cancer
Phase-III
Aged
80 and over
General Medicine
Middle Aged
Prognosis
Immunohistochemistry
Treatment Outcome
030220 oncology & carcinogenesis
Pd l1 expression
Female
Adult
medicine.medical_specialty
Pleural Neoplasms
T-Cells
chemical and pharmacologic phenomena
Neoadjuvant chemotherapy
Programmed cell death ligand 1
03 medical and health sciences
Lymphocytes
Tumor-Infiltrating
Stroma
Internal medicine
Statistical significance
Genetics
medicine
Biomarkers
Tumor
Humans
In patient
Molecular Biology
Aged
Retrospective Studies
Pleural mesothelioma
business.industry
Tumour-infiltrating lymphocyte
Mesothelioma
Malignant
medicine.disease
T-Cell
030104 developmental biology
business
Transcriptome
Zdroj: Molecular biology reports. 46(3)
ISSN: 1573-4978
Popis: Malignant pleural mesothelioma (MPM) is a rare and aggressive form of tumour. Some mesotheliomas have been proven to be highly immunogenic. Here, we investigated the correlation between tumour infiltrating lymphocytes (TILs) or programmed cell death ligand 1 (PD-L1) expression with overall survival (OS) in patients with MPM. 62 Paraffin-embedded formalin fixed (PEFF) samples were analysed for TILs and PD-L1 expression. Patients were divided in 4 groups according to a cut-off of the percentage of TILs found per sample as measured by immunohistichemistry: “0” or absent (between 0 and 5%), “1” or low (between 6 and 25%), “2” or moderate (between 26 and 50%) and “3” or high (between 51 and 75%). OS was then correlated with different TILs’ expression patterns. Moreover, PD-L1 expression was assessed within the tumour as well as in the adjacent stroma on the same samples. Higher expression of peritumoral TILs (Group 2 + 3) versus Group 0 and 1 correlated with improved OS (p-value = 0.02). On the contrary PD-L1 expression seemed to be inversely correlated with clinical outcomes, even in the absence of statistical significance (HR 1.76; p = 0.083 95% IC 0.92–3.36 in areas within the tumour; HR 1.60; p = 0.176 95%; IC 0.80–3.19 in areas within the stroma). No relationship between TILs and PD-L1 expression was identified. Our research supports the use of TILs and PD-L1 expression as potential outcome predictors in patients with MPM. The use of TILs and PD-L1 as biomarkers for checkpoint inhibitors’ efficacy warrants future investigation.
Databáze: OpenAIRE
Externí odkaz: